IN8bio to present new data from Phase 1 trial of INB-100 at EBMT meeting

IN8bio announced that new data from the ongoing Phase 1 trial evaluating INB-100, an allogeneic, gamma-delta T cell therapy, in patients with hematologic malignancies undergoing haploidentical stem cell transplantation, HSCT, will be presented at the 49th Annual Meeting of the European Society for Blood and Marrow Transplantation, EBMT, being held in Paris, France April 23-26. Four patients received dose level 1 of INB-100 and two patients received DL2 as of the abstract data cutoff of December 18, 2022. All four patients who received DL1 remain on study and in durable complete remission, with one patient remaining progression free for nearly three years at 32.2 months and the others remaining progression free for 29.8, 18.1 and 3.8 months respectively. Immune system reconstitution through the first 100-days post-treatment was robust and durable, with observed elevations in T cells, NK cells, and gamma-delta T cells. Updated data from this Phase 1 study will be presented at the meeting on April 23rd, 2023.